OncoMatch

OncoMatch/Clinical Trials/NCT06811844

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

Is NCT06811844 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Two-cycle induction chemotherapy + immunotherapy and Three-cycle induction chemotherapy + immunotherapy for nasopharyngeal neoplasms.

Phase 2RecruitingThe First Affiliated Hospital of Xiamen UniversityNCT06811844Data as of May 2026

Treatment: Two-cycle induction chemotherapy + immunotherapy · Three-cycle induction chemotherapy + immunotherapyThis prospective, phase II, multicenter, randomized controlled study aims to compare the complete response rate and long-term survival outcomes of two-cycle and three-cycle induction therapy with modified TPF regimens combined with camrelizumab in patients with locally advanced nasopharyngeal carcinoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Disease stage

Required: Stage T1-4N2-3M0 (UICC/AJCC TNM staging system, 8th edition)

clinical staging T1-4N2-3M0 (according to the UICC/AJCC TNM staging system, 8th edition)

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Lab requirements

Blood counts

Normal major organ function, with basic normal results in hematology, biochemistry, and coagulation tests

Kidney function

Normal major organ function, with basic normal results in hematology, biochemistry, and coagulation tests

Liver function

Normal major organ function, with basic normal results in hematology, biochemistry, and coagulation tests

Cardiac function

Unwell-controlled cardiac clinical symptoms or diseases [excluded]

Normal major organ function, with basic normal results in hematology, biochemistry, and coagulation tests; Unwell-controlled cardiac clinical symptoms or diseases [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify